NCT01945606 is a Phase 2 clinical trial of BAY1067197 (treatment 2) in Heart Failure, sponsored by Bayer.

Who is sponsoring NCT01945606?

NCT01945606 is sponsored by Bayer.

What drugs are being tested in NCT01945606?

Interventions in NCT01945606: Placebo (treatment 1), BAY1067197 (treatment 2).

What condition does NCT01945606 study?

NCT01945606 studies Heart Failure.

Is NCT01945606 still recruiting?

NCT01945606 is currently completed. Last updated 19 September 2019.

Last reviewed 2019-09-19 · How we verify

NCT01945606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker

Completed Phase 2 Last updated 19 September 2019

What this trial tests

Phase 2 trial testing Placebo (treatment 1) in Heart Failure in 11 participants. Completed in 17 March 2015.

Timeline

29 November 2013

Primary endpoint
9 September 2014

17 March 2015

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	11
Start date	29 November 2013
Primary completion	9 September 2014
Estimated completion	17 March 2015
Sites	1 location across Netherlands

Drugs / interventions tested

Placebo (treatment 1)
BAY1067197 (treatment 2) — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 75, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to investigate the safety and tolerability of the partial A1 agonist BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied as a single dose of 30 mg in addition to standard therapy including a beta-blocker. The aim of the study is to assess if a single oral dose of 30 mg BAY1067197 is well tolerated when given on top of standard therapy for heart failure, particularly ß-blocker treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges.
Sousa JB, Diniz C. · · 2017 · cited 17× · PMID 28481238 · DOI 10.3390/molecules22050752

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01945606 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01945606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing